Cipher Pharmaceuticals Inc (CPH) Insider Buys C$20,535.00 in Stock

Cipher Pharmaceuticals Inc (TSE:CPH) (NASDAQ:CPHR) insider John Mull bought 3,700 shares of the firm’s stock in a transaction dated Wednesday, June 14th. The shares were acquired at an average price of C$5.55 per share, for a total transaction of C$20,535.00.

John Mull also recently made the following trade(s):

  • On Tuesday, June 13th, John Mull bought 5,000 shares of Cipher Pharmaceuticals stock. The shares were acquired at an average price of C$5.55 per share, for a total transaction of C$27,750.00.
  • On Friday, June 9th, John Mull bought 5,000 shares of Cipher Pharmaceuticals stock. The shares were acquired at an average price of C$5.50 per share, for a total transaction of C$27,500.00.
  • On Monday, June 12th, John Mull bought 5,000 shares of Cipher Pharmaceuticals stock. The shares were acquired at an average price of C$5.55 per share, for a total transaction of C$27,750.00.

Cipher Pharmaceuticals Inc (TSE CPH) traded up 0.55% during mid-day trading on Tuesday, reaching $5.53. 3,947 shares of the company were exchanged. Cipher Pharmaceuticals Inc has a 1-year low of $3.50 and a 1-year high of $7.35. The company’s market capitalization is $146.61 million. The company has a 50 day moving average of $5.34 and a 200-day moving average of $4.71.

Insider Buying and Selling by Quarter for Cipher Pharmaceuticals (TSE:CPH)

ILLEGAL ACTIVITY WARNING: “Cipher Pharmaceuticals Inc (CPH) Insider Buys C$20,535.00 in Stock” was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://sportsperspectives.com/2017/06/20/cipher-pharmaceuticals-inc-cph-insider-buys-c20535-00-in-stock.html.

CPH has been the topic of several recent research reports. CIBC upped their target price on shares of Cipher Pharmaceuticals from C$7.00 to C$7.50 in a research report on Wednesday, May 3rd. TD Securities restated a “hold” rating and set a C$4.75 target price on shares of Cipher Pharmaceuticals in a research report on Tuesday, May 2nd. Finally, Bloom Burton upgraded shares of Cipher Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, May 12th.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals Inc is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA.

Receive News & Ratings for Cipher Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply